Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) cratered 74% on April 3rd, after the company received a Complete Response Letter from the FDA concerning its New Drug Application of reproxalap for the treatment of dry eye disease. The FDAI am a private investor based out of Toronto, Canada and I have been investing since 2003. After 8 years in Corporate Finance with a Canadian Telecom company I have decided to dedicate myself full-time to the capital markets. I write on Seeking Alpha to demonstrate my financial a ...